The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2024 | The current landscape of treatment for BPDCN
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the current landscape of treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). He mentions tagraxofusp, a CD123-targeted agent that is approved to treat BPDCN in Europe and the US, as well as pivekimab sunirine, an antibody-drug conjugate showing efficacy in relapsed BPDCN. Additionally, ongoing investigations explore the potential of combining venetoclax with other agents in BPDCN treatment. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Cimeio Therapeutics: Consultant; IDRx: Consultant; Jnana Therapeutics: Consultant; ProteinQure: Consultant; Qiagen: Consultant; Medzown: Stokeholder, SAB; AbbVie: Research Support; Stemline Therapeutics: Research Support.
